The use of botulinum toxin in paediatric hypertonia

Paediatrics and Child Health

Volumn 10, Issue 7, 2005, Pages 379-381

  Fehlings, Darcy ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOLLAND BLOORVIEW KIDS REHABILITATION HOSPITAL   (Canada)

Author keywords

Botulinum toxin; Cerebral palsy; Dystonia; Hypertonia; Spasticity

Indexed keywords

BOTULINUM TOXIN A;

DOSE CALCULATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DYSTONIA; FATIGUE; HUMAN; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; NEUROMUSCULAR BLOCKING; PRACTICE GUIDELINE; REVIEW; SPASTICITY;

EID: 27544454997     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW; Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003;111:e89-97.
2. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:80-99.
3. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-94.
4. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair ot motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200-5.
5. Bakheit AM, Severa S, Cosgrove A, et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 2001;43:234-8. (Erratum in 2001;43:357)
6. Herrmann J, Mall V, Bigalke H, Geth K, Korinthenberg R, Heinen F. Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy. Neuropediatrics 2000;31:333-4.
7. Boyd RN, Hays RM. Outcome measurement of effectiveness of botulinum toxin type A in children with cerebral palsy: An ICIDH-2 approach. Eur J Neurol 2001;8(Suppl 5):167-77.
8. Ubhi T, Bhakta BB, Ives HL, Allgar V, Roussounis SH. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000;83:481-7.
9. Barwood S, Baillieu C, Boyd R, et al. Analgesic effects of botulinum toxin A: A randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000;42:116-21.
10. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: A multicenter, open-label clinical trial. Pediatrics 2001;108:1062-71.
11. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: A double-blind trial. Dev Med Child Neurol 1997;39:185-93.
12. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000;137:331-7.
13. Fehlings D, Rang M, Glazier J, Steele C. Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: Child characteristics that predict a positive outcome. Eur J Neurol 2001;8(Suppl 5):145-9.
14. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: A randomised prospective trial. J Pediatr Orthop 1998;18:304-11.
15. Flett PJ, Stern LM, Waddy H, Connell TM, Seeger JD, Gibson SK. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 1999;35:71-7.
16. Russman BS, Tilton A, Gormley ME Jr. Cerebral palsy: A rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl 1997;6:S181-93.